AbbVie’s recent confirmation that it’s in talks to acquire Gilgamesh Pharmaceuticals for roughly $1 billion underscores its unrelenting push to...
Read moreDetailsUS stocks traded higher on Wednesday, with the benchmark S&P 500 rising by 0.7%, the Nasdaq climbing by 0.9%, and...
Read moreDetailsAccording to a report by StreetInsider, an unnamed strategic buyer has offered $18 per share for the company, prompting Axogen...
Read moreDetailsOpendoor Technologies (OPEN) surged a massive 245% in July, capturing the attention of investors and analysts alike.
Read moreDetailsU.S. stocks dipped on Tuesday as Wall Street digested the latest release of corporate earnings, global trade tensions, and mixed...
Read moreDetailsComerica Inc. has recently found itself at the center of M&A speculation following a public push from HoldCo Asset Management...
Read moreDetailsPalo Alto Networks is reportedly in advanced talks to acquire CyberArk Software in a deal that could exceed $20 billion,...
Read moreDetailsCoinbase (COIN) is facing a setback after analysts at Compass Point downgraded the stock, citing concerns over its sustainability amid...
Read moreDetailsUS stocks made a comeback on Monday, recovering from the previous week’s steep sell-off, triggered by weaker-than-expected labor data and...
Read moreDetailsBaker Hughes is making headlines with its pursuit of a transformative $13.6 billion all-cash acquisition of Chart Industries, a move...
Read moreDetailsThese Next Steps are EXTREMELY IMPORTANT because the only way to get our Featured Top Stock Alerts is to reply back to the message you just received by answering YES.
CLICK HERE TO REPLY BACK
YES ON YOUR CELL PHONE
To make sure you are in, please check your cell phone for a message from 16462224464 (make sure you save that number on your contacts under "StockTips") If you don't see the message check "Unknown Senders" on your phone.
If you did not receive the text message on your cell phone, then grab your phone right now and text the word "MOMO" to "16462224464"
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.